The race to develop an effective oral GLP-1 drug just got more competitive. AstraZeneca announced this week that it’s moving elecoglipron - an oral GLP-1 receptor agonist in pill form - into an “extensive” Phase 3 development program. The decision follows positive results from two mid-stage studies published in The Lancet.
This is worth paying attention to, because the oral GLP-1 space is shaping up to be one of the most competitive corners of obesity research.
What the Phase 2 Data Showed
The numbers from AstraZeneca’s Phase 2 obesity study are solid, if not spectacular:
- 10.5% average weight loss at 26 weeks
- 11.8% average weight loss at 38 weeks
- A separate diabetes study showed blood sugar reductions of approximately 2%
For comparison, injectable semaglutide (Wegovy) typically produces 15-17% weight loss over 68 weeks, and tirzepatide (Zepbound) reaches 20-22% over 72 weeks. Elecoglipron’s numbers are lower, but the key differentiator is that it’s a daily pill rather than a weekly injection.
Analysts at Jefferies described the weight loss data as “ahead of expectations” and noted that the results enable AstraZeneca to make a “strong case” for using elecoglipron in drug combinations. That combination angle could be critical for the next wave of obesity treatments.
Why Oral Matters
The demand for oral GLP-1 alternatives is real and well-documented. Injectable GLP-1 compounds require refrigeration, proper injection technique, and weekly administration. For many people, a daily pill would be significantly more practical.
The challenge is that GLP-1 receptor agonists are peptides - chains of amino acids that get broken down by stomach acid. Current injectable versions work because they bypass the digestive system entirely. Making an oral version that survives the gut and still activates the GLP-1 receptor is a genuine scientific challenge.
Elecoglipron takes a different approach. Rather than being a peptide, it’s a small molecule designed to activate the GLP-1 receptor directly. This means it can survive the digestive system and be absorbed through the gut lining - no injection required.
The Competitive Landscape for Oral GLP-1s
AstraZeneca isn’t the only company working on this. The oral GLP-1 space is getting crowded:
Eli Lilly - Orforglipron (brand name Foundayo) The most advanced oral GLP-1 agonist. Lilly recently launched Foundayo after Phase 3 trials showed meaningful weight loss. It’s seen by analysts as a future blockbuster and represents Lilly’s attempt to dominate both the injectable and oral obesity markets.
Novo Nordisk - Amycretin A once-daily oral GLP-1 and amylin co-agonist. Phase 2 data showed strong weight loss results, and Novo is advancing it through clinical testing.
Pfizer - (post-danuglipron pivot) Pfizer’s earlier oral GLP-1 candidate danuglipron was discontinued after disappointing results. The company has since pivoted to its Metsera acquisition pipeline, which focuses on injectable compounds.
AstraZeneca’s entry with elecoglipron adds another major player to this field. The company has deep commercial infrastructure globally, which could give it an advantage in reaching markets where Lilly and Novo are already established.
What the Research Says
The Lancet publication is significant. Peer-reviewed data in a top-tier medical journal carries more weight than conference presentations or press releases. The fact that both the obesity and diabetes studies were published together suggests the journal’s reviewers found the data compelling.
Key details from the published research:
- The obesity study enrolled participants with a BMI of 30 or higher (or 27+ with weight-related conditions)
- Dose-dependent effects were observed, with higher doses producing greater weight loss
- Gastrointestinal side effects (nausea, vomiting, diarrhoea) were the most common adverse events, consistent with the GLP-1 agonist class
- The diabetes study showed clinically meaningful reductions in HbA1c (a measure of long-term blood sugar control)
The Combination Strategy
One of the most interesting aspects of AstraZeneca’s announcement is the emphasis on drug combinations. Jefferies analyst Michael Leuchten noted that elecoglipron’s profile makes it suitable for pairing with other compounds.
This is becoming a major theme in obesity research. The idea is that combining drugs with different mechanisms of action could produce greater weight loss than any single compound alone. For example:
- A GLP-1 agonist (appetite suppression) + a GIP agonist (metabolic effects)
- An oral GLP-1 pill + an injectable compound for additional weight loss
- A GLP-1 agonist + a compound targeting muscle preservation
If AstraZeneca can develop elecoglipron as part of a combination regimen, it could potentially match or exceed the weight loss seen with injectable monotherapies while maintaining the convenience of a pill.
What to Watch Next
The Phase 3 program for elecoglipron is expected to be large and multi-faceted. Key milestones include:
- Phase 3 trial design - likely to include both obesity and diabetes endpoints
- Dosing optimisation - whether once-daily dosing at the optimal dose can close the gap with injectables
- Combination trials - pairing elecoglipron with other AstraZeneca compounds
- Regulatory timeline - if Phase 3 goes well, a filing could come as early as 2028
We’ll be keeping an eye on elecoglipron as it advances. The oral GLP-1 space is one of the most active areas of obesity research right now, and AstraZeneca’s entry makes it even more competitive.
This article is for educational and informational purposes only. It does not constitute medical advice, therapeutic recommendations, or endorsements of any compound. Grey Highway is a research-education community. We do not sell, supply, or promote the use of research compounds. Always consult a qualified healthcare professional regarding health decisions. For Australian regulatory information, visit the TGA website.
Sources
- BioPharma Dive: “AstraZeneca’s ’extensive’ obesity drug push” (10 June 2026) - biopharmadive.com
- Elecoglipron Phase 2 results published in The Lancet (June 2026)
- BioPharma Dive: “ADA ‘26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ option” (8 June 2026) - biopharmadive.com